77 terminated. 77 Phase 2, 23 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 77 | Terminated 77 |
| Phase 1 | 23 | Terminated 23 |
| Phase 3 | 5 | Terminated 5 |
Follow Hepatocellular Carcinoma: new trials by email Literature Review of Hepatocellular Carcinoma trials Research Report on Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2023-09-27 | 2026-06-18 |
| Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization - Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Terminated | Yale University | 3 | 2023-06-07 | 2025-01-15 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma F18-FDG, MRI, CT - Hepatocellular Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2023-01-18 | 2025-08-28 |
| Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma Ezurpimtrostat, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | University Hospital, Grenoble | 3 | 2022-12-15 | 2025-04-20 |
| Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Axitinib, Avelumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2022-11-04 | 2023-05-03 |
| KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) KAT-101, KAT-201 - Hepatocellular Carcinoma, Fibrolamellar Carcinoma | Phase 1 / Phase 2 | Terminated | Primocure Pharma | 1 | 2022-11-01 | 2026-10-27 |
| Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy Neoadjuvant - Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis | Phase 2 | Terminated | Ontario Clinical Oncology Group (OCOG) | 1 | 2022-10-18 | 2025-03-11 |
| T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma T-ACE Oil, Lipiodol - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | T-ACE Medical Co., Ltd | 2 | 2022-09-13 | 2026-08-18 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Nanrilkefusp Alfa, Pembrolizumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 2 | Terminated | SOTIO Biotech AG | 166 | 2022-06-21 | 2025-11-17 |
| Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma Casdozokitug, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | Coherus Oncology, Inc. | 30 | 2022-04-12 | 2026-10-01 |
| Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors SD-101, Pembrolizumab, Nivolumab - Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Terminated | TriSalus Life Sciences, Inc. | 23 | 2022-03-02 | 2025-10-23 |
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. HAIC, TACE, FOLFOX - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Terminated | Peking University | 18 | 2021-12-24 | 2025-12-18 |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant Durvalumab, Tremelimumab, Liver Transplant - Hepatocellular Carcinoma, Cirrhosis | Phase 2 | Terminated | University of Cincinnati | 8 | 2021-12-07 | 2026-05-06 |
| Study of INCB086550 in Select Solid Tumors INCB086550 - Non Small Cell Lung Cancer, Urothelial Cancer | Phase 2 | Terminated | Incyte Corporation | 16 | 2021-09-02 | 2025-03-13 |
| Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib TheraBionic, Regorafenib - Hepatocellular Carcinoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 2 | 2021-01-26 | 2026-03-05 |
| Optimization for Regorafenib in HCC Regorafenib 40 MG - Hepatocellular Carcinoma | Phase 2 | Terminated | SC Liver Research Consortium, LLC | 7 | 2021-01-21 | 2021-12-30 |
| Perioperative Therapy for Hepatocellular Carcinoma Sintilimab Injection, TACE, Radiotherapy - Hepatocellular Carcinoma | Phase 2 | Terminated | Zhejiang University | 10 | 2020-12-26 | 2022-01-11 |
| Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Y-90 TARE, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | Aiwu Ruth He, MD | 6 | 2020-11-30 | 2024-06-05 |
Showing 20 of 77. Sign in to see all of them.
Carcinoma, Hepatocellular (77) · Liver Neoplasms (15) · Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Cholangiocarcinoma (5) · Colorectal Neoplasms (5) · Carcinoma, Renal Cell (4) · Stomach Neoplasms (4) · Fibrosis (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma (2)
Digestive System Diseases (77) · Adenocarcinoma (76) · Digestive System Neoplasms (76) · Liver Diseases (76) · Neoplasms by Histologic Type (76) · Neoplasms by Site (76) · Neoplasms, Glandular and Epithelial (76) · Carcinoma (75) · Neoplasms (70) · Liver Neoplasms (62) · Pathological Conditions, Signs and Symptoms (8) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Pathologic Processes (7) · Endocrine Gland Neoplasms (6)
Sorafenib (9) · Nivolumab (7) · Bevacizumab (6) · atezolizumab (6) · pembrolizumab (3) · Capecitabine (2) · Cisplatin (2) · Erlotinib Hydrochloride (2) · Fluorouracil (2) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (2) · Leucovorin (2) · Oxaliplatin (2) · TLC 388 (2) · avelumab (2) · durvalumab (2)
University of Texas Southwestern Medical Center (3) · Abramson Cancer Center at Penn Medicine (2) · Assistance Publique - Hôpitaux de Paris (2) · National Cancer Institute (NCI) (2) · New Mexico Cancer Research Alliance (2) · Taiwan Liposome Company (2) · Zhejiang University (2) · AVEO Pharmaceuticals, Inc. (1) · Adherex Technologies, Inc. (1) · Aiwu Ruth He, MD (1) · Alaunos Therapeutics (1) · Antengene Therapeutics Limited (1) · Apollomics (Australia) Pty. Ltd. (1) · Auron Healthcare GmbH (1) · BTG International Inc. (1)
United States (39) · Taiwan (17) · South Korea (10) · China (9) · France (8) · Singapore (7) · Belgium (5) · Canada (4) · Germany (4) · Hong Kong (4) · Italy (4) · Hungary (3) · Poland (3) · United Kingdom (3) · Australia (2)
David Hsieh, MD (2) · A. Erhardt, PD Dr. (1) · Aiwu R He, MD PhD (1) · Aiwu R He, MD, PhD (1) · Alain Hendlisz, MD (1) · Ari D Baron, MD (1) · Brandon Meyers, MD (1) · Carl Brown, PhD (1) · Catherine T Frenette, MD (1) · Chau-Ting Yeh, MD (1) · Chung Hu Chan, MD, PHD (1) · Claire Daugherty, MS (1) · Davendra Sohal, MD (1)
PMID 20724077, PMID 22210086, PMID 22913492, PMID 23316013, PMID 23331661, PMID 23397536, PMID 24012941, PMID 24251922, PMID 24657396, PMID 25173458, PMID 26449224, PMID 27681866, PMID 28687627, PMID 29486918, PMID 35043976, PMID 35258371, PMID 35949290, PMID 36367894, PMID 36912078, PMID 39563886, PMID 42259602
2008 (1), 2018 (1), P30CA012197 (1), R01CA218486 (1)